Viveve Medical, Inc. (VIVE)
OTCMKTS: VIVE · Delayed Price · USD
0.0004
0.00 (0.00%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Viveve Medical Revenue
Viveve Medical had revenue of $1.68M in the quarter ending September 30, 2022, with 4.21% growth. This brings the company's revenue in the last twelve months to $6.83M, up 2.38% year-over-year. In the year 2021, Viveve Medical had annual revenue of $6.43M with 17.28% growth.
Revenue (ttm)
$6.83M
Revenue Growth
+2.38%
P/S Ratio
0.00
Revenue / Employee
$145,234
Employees
47
Market Cap
4.29K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2021 | 6.43M | 947.00K | 17.28% |
Dec 31, 2020 | 5.48M | -1.09M | -16.57% |
Dec 31, 2019 | 6.57M | -11.95M | -64.54% |
Dec 31, 2018 | 18.52M | 3.23M | 21.12% |
Dec 31, 2017 | 15.29M | 8.15M | 114.09% |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Dec 31, 2013 | Pro | Pro | Pro |
Dec 31, 2012 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
AstraZeneca | 49.13B |
Novartis AG | 48.86B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
VIVE News
- 1 year ago - Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence - Accesswire
- 1 year ago - Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded - Accesswire
- 1 year ago - Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence - Accesswire
- 1 year ago - Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Accesswire
- 1 year ago - Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022 - Accesswire
- 1 year ago - Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence - Accesswire
- 2 years ago - Viveve to Participate in Ladenburg Thalmann Healthcare Conference - Accesswire
- 2 years ago - Viveve to Participate in Alliance Global Partners Virtual MedTech Conference - Accesswire